Sustainability: Pharma Reaches Above the Low-Hanging Fruit

May 17, 2012

Those who cover green and sustainability issues know that Pharma is pretty progressive. No, the industry's not perfect, certainly, but many of its leading companies also make it a point to be leaders in environmental stewardship. While more drug companies are successfully jumping on the green bandwagon, it's getting harder and harder to find projects that make a real difference. In other words, the low-hanging fruit has been picked. So what's next?

Those who cover green and sustainability issues know that Pharma is pretty progressive. No, the industry's not perfect, certainly, but many of its leading companies also make it a point to be leaders in environmental stewardship. While more drug companies are successfully jumping on the green bandwagon, it's getting harder and harder to find projects that make a real difference. In other words, the low-hanging fruit has been picked. So what's next?

In Pharmaceutical Manufacturing's May cover story, we look at what's next--five projects from five companies who are leaders in sustainability: AstraZeneca, Pfizer, Bayer, DSM Pharmaceutical Products, and EMD Millipore. These are just a few of the companies that continue to embrace green as a marketing strategy, as a competitive advantage, and as the right thing to do.

Also in our May issue, co-authors from Biogen Idec and Veolia talk about a combined heat and power (CHP) project they recently undertook. Here are links below--enjoy the fruits of our labor.

Cover Story:

Pharma Sustainability Is on a Roll

Sidebars:

EMD Millipore: Giving and Receiving Single-Use Systems

Bayer: Keeping Data Cold and Green

Pfizer Newbridge Powers Up

Feature:

Biogen and Veolia: Optimizing the Energy Efficiency of Research and Manufacturing Processes

--Paul Thomas

About the Author

pharmamanufacturing | pharmamanufacturing